New oral pill aims to fight RSV in adults
NCT ID NCT03699202
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called AK0529 (Ziresovir) in adults aged 18 to 75 with respiratory syncytial virus (RSV) infection. Participants receive either the drug or a placebo, and researchers measure how well symptoms improve and track any side effects. The goal is to see if AK0529 can safely reduce RSV symptoms and viral load.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK0529 (Ziresovir)
What this could lead to
If successful, this could provide a new oral treatment option for adults with RSV infection, potentially reducing symptoms and viral load.
What could go wrong
This is an early phase 2 trial with a small number of participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Zunyi Medical University
Zunyi, 563000, China
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China
-
Beijing Ditan Hospital
Beijing, Beijing Municipality, 100015, China
-
Beijing Pinggu Hospital
Beijing, 101200, China
-
Central Hospital of Minhang District, Shanghai
Shanghai, 201199, China
-
China-Japan Friendship Hospital
Beijing, 100029, China
-
Huizhou Municipal Central Hospital
Huizhou, Guangdong, 516001, China
-
Jiangsu Taizhou People's Hospital
Taizhou, Jiangsu, 225300, China
-
Nanjing First Hospital
Nanjing, Jiangsu, 210006, China
-
Nantong First People's Hospital
Nantong, 226001, China
-
People's Hospital of Deyang City
Deyang, Sichuan, 618000, China
-
Qingdao Municipal Hospital
Qingdao, Shandong, 266011, China
-
Quanzhou First Hospital
Quanzhou, Fujian, 362000, China
-
Sanya Central Hospital
Sanya, Hainan, 572000, China
-
Shanghai East Hospital
Shanghai, 200120, China
-
Shenzhen People's Hospital
Shenzhen, 518001, China
-
Suining Central Hopital
Suining, Sichuan, 629000, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, 233004, China
-
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, 571199, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
Xiangtan Central Hospital
Xiangtan, 411100, China
-
Xinxiang First People's Hospital
Xinxiang, 453000, China